COVID PILL
From claiming a COVID cure to receiving an anonymous letter: The unfolding of the Patanjali case
The Supreme Court has criticized the Uttarakhand authorities for failing to act against Patanjali Ayurved, founded by Ramdev and Balkrishna. Rejecting apologies from the duo, the court questioned the consumption of Patanjali medicines for incurable diseases. The timeline includes the launch of Coronil, a claimed COVID-19 treatment, and subsequent controversies. The court's scrutiny follows a petition by the Indian Medical Association against Patanjali's misleading advertisements, highlighting the importance of truthfulness in healthcare claims.
Diabetes drug may be the pill for long Covid
Taking the diabetes drug metformin within three days of testing positive for Covid-19 may reduce the risk of developing long Covid by 40%, according to a study. The US trial, reported in the Lancet, involved 1,126 overweight and obese patients, 35 of whom were diagnosed with enduring symptoms after taking metformin versus 58 on a placebo. The study did not assess the impact of the drug on those already suffering from long Covid.
Pharma has to find new growth pills as Covid booster wears off
The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
Generic drug companies in no hurry to launch new Covid products
BDR Pharmaceuticals, a Mumbai-based active pharmaceutical ingredient (API) manufacturing company, has developed the API of antiviral pill Paxlovid and can manufacture the drug but it has decided to wait and watch, Shah said. "We will see if there is any need in the country to launch it," he told ET. "At present, cases are mild and are recovering with the conventional treatment."
Drugmakers seem to be in no hurry to launch Covid antiviral pill Paxlovid
Several industry executives and doctors ET spoke to said at the moment, while cases are rising, the need for Paxlovid hasn't been felt as cases are mild and they also pointed to the bitter experience they had with molnupiravir in third wave, where they were left with lots of unsold stock and had to take write-offs.
Pills to wellness, Cipla is seeking a new identity
One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possible by pursuing selective yet complex generic portfolios. Cipla entered US in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 mn in 2015.
- Go To Page 1
Pills to wellness, Cipla is seeking a new identity
One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible by pursuing selective yet complex generic portfolios. Cipla entered the US market in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015. From FY15 to FY21, Cipla's US revenue grew close to five times. The US business contributed around one-fifth of the total revenue of ₹19,160 crore in FY21.
Optimus too could launch Covid pill Paxlovid soon
The company has conducted bioavailability and bioequivalence (BA/BE) studies and is likely to submit the safety data to the drug regulator this week for a review, said people aware of the matter.
19 Indian companies get licence to make Pfizer's oral generic
These include Cipla, Sun Pharma, Laurus Labs, Divi's Laboratories, Glenmark, Emcure, Macleods, SMS Pharmaceuticals, Strides, Torrent, Cadila, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, and Viatris, among others.
Torrent & Cadila Pharmaceuticals get license to manufacture oral antiviral Covid-19 pill nirmatrelvir
Torrent said that t it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with MPP. Cadila said that it will cater to Indian and export markets since many countries with high Covid-19 burden lack access to effective therapy.
Torrent & Aurobindo receive licenses to sell Pfizer's COVID pill Paxlovid in India, low income countries
The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations.
How does Merck's COVID-19 pill compare to Pfizer's?
Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patients at risk of severe COVID who were given the treatment within five days of developing symptoms.
SEC no to clinical trial waiver for Pfizer's Covid pill
The SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, said people with knowledge of the matter.
MSN to launch generic anti-COVID pill Molnupiravir under 'Molulow' brand
The group is all set to launch the generic Molnupiravir 200 mg capsules and it is being manufactured at its USFDA and MHRA accredited facility based out of Hyderabad, MSN Group said in a statement. Molulow will come as a pack of 4x10 capsule strips with each capsule in 200 mg strength.
Dr Reddy's launches molnupiravir at Rs 35 per pill, matching Mankind's price
Dr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 days costing Rs. 1,400 making it among the most affordable treatment options available to patients.
Mankind, BDR Pharma join hands to launch anti COVID-19 pill Molulife
Mankind Pharma on Wednesday said it has joined hands with BDR Pharmaceuticals to launch oral anti-COVID-19 pill Molulife (Molnupiravir) in the country. The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma, the company said in a statement.
Domestic pharma companies gear up to launch Merck's Covid pill
Union health minister Mansukh Mandaviya said 13 companies in India will manufacture the drug approved for restricted use under emergency situation for treatment of adult patients who have high risk of progression of Covid-19.
Government panel recommends EUA for COVID-19 vaccines Covovax, Corbevax and anti-Covid pill molnupiravir
The SEC on COVID-19 of the CDSCO, which reviewed the emergency use authorisation (EUA) applications of Serum Institute of India (SII) for the second time on Monday, after detailed deliberation has recommended granting EUA to Covovax.
USFDA approves COVID antiviral pill molnupiravir for emergency use
The USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. The regulatory agency said molnupiravir should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
Pfizer pill becomes 1st US-authorized home COVID treatment
Data from Pfizer's clinical trial showed its two-drug antiviral regimen was 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness. Recent lab data suggests the drug retains its effectiveness against Omicron.
Pfizer confirms COVID pill's results, potency versus omicron
The Food and Drug Administration is expected to soon rule on whether to authorize Pfizer's pill and a competing pill from Merck, which was submitted to regulators several weeks earlier. If granted, the pills would be the first COVID-19 treatments that Americans could pickup at a pharmacy and take at home.
Expert panel asks drug cos to submit subgroup data on Molnupiravir
Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate Covid-19 in adults.
Dr Reddy’s, Merck’s Covid pill partner in India, sees a short-lived boom
And this is despite Dr Reddy’s, one of India’s largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod to produce Merck’s antiviral drug molnupiravir within weeks. The reason: multiple licensees for the Merck drug will cap profits and manufacturing glitches for Sputnik have led to loss of precious time as the world’s second-most populous nation was ramping up its inoculation drive.
Pfizer to allow generic versions of its COVID-19 pill in 95 countries
The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.
Dr. Reddy's open to making Pfizer COVID pill after Merck deal
The new drugs, which unlike vaccines can be used to treat patients once they contract coronavirus infection, are expected to be a huge market. Merck has given out licenses to manufacturers in developing countries to ensure a swift global supply, and companies are hopeful that Pfizer will do the same.
Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%
Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.
Merck to seek emergency approval for experimental pill that cuts worst effects of coronavirus
If cleared, Merck's drug - molnupiravir - would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorized in the U.S. require an IV or injection.
Load More
